Skip to main content
Top
Published in: Clinical Rheumatology 6/2003

01-12-2003 | Original Article

Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate

Authors: Sreekanth Vasireddy, Amruta Talwalkar, Hazel Miller, Rakesh Mehan, David R. Swinson

Published in: Clinical Rheumatology | Issue 6/2003

Login to get access

Abstract

Two-thirds of patients with Paget’s disease seeking medical attention present with pain. We studied patterns of pagetic pain in relation to physical activity, and the effect of coexistent osteoarthritis (OA)/pagetic arthropathy on pain and physical activity before and after treatment with pamidronate. Patients with lower-segment Paget’s disease (lumbar spine, pelvis or lower limbs), raised alkaline phosphatase (ALP), and pain as a symptom were included. Two subgroups were identified based on the absence (P group), or presence (POA group) of radiological OA in the lower segment. They received 2–4 fortnightly infusions of pamidronate 30–60 mg and were followed up at 6 weeks, 3 months and 6 months. Outcome measures were visual analog scales for pain at rest, on standing, on walking and at night; standing time, walking distance, 50-yard walking time, and ALP. Twenty-five patients (12 men, 13 women, mean age 70.1±1.9 years), received a mean of 142±9.7 mg of pamidronate. The P group had higher mean ALP (p=0.003) and higher scores for pain (not significant) at baseline than the POA group. Compared to baseline, P group had significant improvements (p<0.01) at 6 months in rest pain, standing pain and walking pain. The POA group had non-significant changes in pain at 6 months. ALP improved significantly at 6 months in both subgroups (p<0.01). The whole group also improved at 6 months in standing time (55.7%, not significant), walking distance (33.9%, not significant), and 50-yard walking time (24.2%, p<0.05). Paget’s patients with coexistent joint disease had less severe pain and bone disease at baseline than those without coexistent joint disease, and responded less well to pamidronate, although they did have significant improvement in ALP levels. Radiographic assessment for coexisting joint disease prior to treatment might improve prognostication from the patient’s point of view, and improve treatment compliance.
Literature
1.
go back to reference Barker DJP (1984) The epidemiology of Paget’s disease of bone. Br Med Bull 40:396–400PubMed Barker DJP (1984) The epidemiology of Paget’s disease of bone. Br Med Bull 40:396–400PubMed
2.
go back to reference Tiegs RD (1997) Paget’s disease of bone: indications for treatment and goals of therapy. Clin Ther 19:1309–1329CrossRefPubMed Tiegs RD (1997) Paget’s disease of bone: indications for treatment and goals of therapy. Clin Ther 19:1309–1329CrossRefPubMed
3.
go back to reference Hamdy RC, Moore S, LeRoy J (1993) Clinical presentation of Paget’s disease of the bone in older patients. South Med J 86:1097–1100PubMed Hamdy RC, Moore S, LeRoy J (1993) Clinical presentation of Paget’s disease of the bone in older patients. South Med J 86:1097–1100PubMed
4.
go back to reference Winfield J, Stamp TC (1984) Bone and joint symptoms in Paget’s disease. Ann Rheum Dis 43:769–773PubMed Winfield J, Stamp TC (1984) Bone and joint symptoms in Paget’s disease. Ann Rheum Dis 43:769–773PubMed
5.
go back to reference Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 308:226–233PubMed Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 308:226–233PubMed
6.
go back to reference Wimalawansa SJ, Gunasekara RD (1993) Pamidronate is effective for Paget’s disease of bone refractory to conventional therapy. Calcif Tissue Int 53:237–241PubMed Wimalawansa SJ, Gunasekara RD (1993) Pamidronate is effective for Paget’s disease of bone refractory to conventional therapy. Calcif Tissue Int 53:237–241PubMed
7.
go back to reference Gutteridge DH, Retallack RW, Ward LC et al. (1996) Clinical, biochemical, hematalogic, and radiographic responses in Paget’s disease following intravenous pamidronate disodium: a 2-year study. Bone 19:387–394CrossRefPubMed Gutteridge DH, Retallack RW, Ward LC et al. (1996) Clinical, biochemical, hematalogic, and radiographic responses in Paget’s disease following intravenous pamidronate disodium: a 2-year study. Bone 19:387–394CrossRefPubMed
8.
go back to reference Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ (1999) Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rhum (Engl Ed) 66:467–476 Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ (1999) Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rhum (Engl Ed) 66:467–476
9.
go back to reference Lyles KW, Lammers JE, Shipp KM et al. (1995) Functional and mobility impairments associated with Paget’s disease of bone. J Am Geriatr Soc 43:502–506PubMed Lyles KW, Lammers JE, Shipp KM et al. (1995) Functional and mobility impairments associated with Paget’s disease of bone. J Am Geriatr Soc 43:502–506PubMed
10.
go back to reference Fitton A, McTavish D (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289–318PubMed Fitton A, McTavish D (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289–318PubMed
11.
go back to reference Flores RH, Hochberg MC (1998) Definition and classification of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York, Oxford University Press, 1–12 Flores RH, Hochberg MC (1998) Definition and classification of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York, Oxford University Press, 1–12
12.
go back to reference Ibbertson HK, Henley JW, Fraser TR et al. (1979) Paget’s disease of bone – clinical evaluation and treatment with diphosphonate. Aust NZ J Med 9:31–35 Ibbertson HK, Henley JW, Fraser TR et al. (1979) Paget’s disease of bone – clinical evaluation and treatment with diphosphonate. Aust NZ J Med 9:31–35
13.
go back to reference Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. London, Martin Dunitz, 111–113 Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. London, Martin Dunitz, 111–113
Metadata
Title
Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate
Authors
Sreekanth Vasireddy
Amruta Talwalkar
Hazel Miller
Rakesh Mehan
David R. Swinson
Publication date
01-12-2003
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 6/2003
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0762-x

Other articles of this Issue 6/2003

Clinical Rheumatology 6/2003 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine